title: The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.
abstract: Lung adenocarcinoma remains to be a high-mortality disease with few effective prognostic biomarkers. Novel biomarkers are urgently demanded to supplement the current prognostic biomarkers. Here, we explored the prognostic value of CYP3A4 and CYP3A5 in lung adenocarcinoma. The tissue microarray was made up of lung adenocarcinoma samples and corresponding normal lung tissues from Nanjing Medical University affiliated Cancer Hospital Tissue Bank. The expression of CYP3A4, together with CYP3A5, was detected by the chip data from Gene Expression Omnibus datasets and immunohistochemistry staining of the tissue microarray. Then, we assessed the relationships between CYP3A4 or CYP3A5 expression level and clinicopathological factors to estimate the clinical significance. Kaplan-Meier curves were applied to analyze the prognosis. Univariate and multivariate Cox analyses were subsequently applied to identify the independent prognostic factors. Immunohistochemistry staining results showed that by comparison with matched normal tissues, CYP3A4 was frequently hyper-expressed in lung adenocarcinoma tissues while CYP3A5 was hypo-expressed, which was consistent with the Gene Expression Omnibus analysis. Kaplan-Meier analysis indicated that high-CYP3A4 or low-CYP3A5 expression level predicted poor survival in lung adenocarcinoma patients. Multivariate Cox analysis found that hypo-expression of CYP3A5 was an independent prognostic factor. Further study revealed that combination of these two markers exhibited a more powerful predictor of poor prognosis, which could target to more accurate survival of lung adenocarcinoma. Our findings indicate that combination of CYP3A4 and CYP3A5 may serve as a novel prognostic biomarker in lung adenocarcinoma, which contribute to the precision of predicting the survival in lung adenocarcinoma.
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|2 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Mao
authors.initials: M
authors.lastname: Qixing
authors.affiliation: 4 Department of Oncology, Jiangsu Province Geriatric Hospital, Nanjing, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Juqing
authors.affiliation: 5 Nanjing Medical University, Nanjing, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Yajing
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Gaochao
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|2 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Wenjie
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|2 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Shi
authors.initials: S
authors.lastname: Run
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|2 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Anpeng
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Lin
authors.affiliation: 1 Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.|3 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Jiang
authors.initials: J
authors.lastname: Feng
authors.affiliation: 4 Department of Oncology, Jiangsu Province Geriatric Hospital, Nanjing, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Jun
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D051544:Cytochrome P-450 CYP3A / Q000032:analysis*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D014408:Biomarkers, Tumor; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
keywords: CYP3A4; CYP3A5; lung adenocarcinoma; prognostic biomarker